JOURNAL ARTICLE

FDA Approves Non-Stimulant ADHD Medication.

  • Published In: Formulary Watch, 2024. P. 1 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Myshko, Denise 3 of 3

Abstract

The article offers information on the FDA approval of Tris Pharma's Onyda XR (clonidine hydrochloride) for patients 6 years of age and older with ADHD. Topics include the availability of Onyda XR as a once-a-day extended-release oral suspension, its potential use as monotherapy or adjunctive therapy, the expected availability in pharmacies in the second half of 2024, and Tris Pharma's plans for pricing and coverage details closer to launch.

Additional Information

  • Source:Formulary Watch. 2024/05, p1
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2024
  • ISSN:2767-3359
  • Accession Number:177643208

Looking to go deeper into this topic? Look for more articles on EBSCOhost.